Real-World Study Compares Weight Loss Drugs for Non-Diabetic Adults

The global prevalence of overweight and obesity continues to rise, posing significant public health challenges due to associated comorbidities like cardiovascular disease and metabolic syndrome. While GLP-1 receptor agonists have shown efficacy in type 2 diabetes and weight management, there's a critical need for comparative, real-world data on their effectiveness and safety specifically in adults with overweight or obesity who do not have diabetes. This study addresses the knowledge gap regarding the comparative performance of Tirzepatide, Semaglutide, and Liraglutide in a non-diabetic, real-world setting.

The study revealed significant differences in weight loss efficacy among the three medications. Patients receiving Tirzepatide achieved the most substantial weight reduction, with a mean body weight loss of 15.3% from baseline, significantly outperforming the other groups (p<0.001). Semaglutide-treated individuals experienced a mean weight loss of 12.1%, while those on Liraglutide showed a mean reduction of 8.4%. Tirzepatide demonstrated superior efficacy, with 82% of patients achieving at least 5% body weight loss, compared to 71% for Semaglutide and 58% for Liraglutide. Furthermore, 45% of the Tirzepatide group achieved >15% weight loss, versus 28% for Semaglutide and 15% for Liraglutide. Adverse event profiles were generally consistent with known side effects for each drug, primarily gastrointestinal, with no new safety signals identified across the 12-month observation period.